AZN Analysis & News - AstraZeneca Group plc | Seeking Alpha

AZN

AstraZeneca Group plc | NYSE

1d 5d 1m 6m 1y 5y 10Y MAX Advanced Chart

52wk high:39.76

52wk low:31.99

EPS (FWD):1.64

PE (FWD):22.94

Div Rate (FWD):1.76

Yield (FWD):4.70%

Market Cap:$94.88B

Volume:

Analysis

Stocks To Watch: Calling Up Animal Spirits
SA Stocks To Watch•Today, 8:26 AM•1 Comment
AstraZeneca Receives FDA Approval For Rare B-Cell Lymphoma Drug Lumoxiti
Terry Chrisomalis•Tue, Sep. 18
AstraZeneca Looks To Its Asthma Drug For Blockbuster Potential
Terry Chrisomalis•Mon, Sep. 10
Your Daily Scoop: Anifrolumab Flunks, Aquestive Approved, Vertex's CRISPR Trial In Germany
Avisol Capital Partners•Mon, Sep. 3•2 Comments
How The Diabetes Market May Soon Cross Over Into Parkinson's
Christiana Friedman•Mon, Jul. 30•9 Comments
AstraZeneca's Late-Stage Study Win Reinforces Its Hold On Particular Segment Of Lung Cancer Market
Terry Chrisomalis•Tue, May 29•1 Comment
AstraZeneca Sees A Phase 3 Flop, But Not All Is Lost
Terry Chrisomalis•Mon, May 14•2 Comments
How Will This Unexpected War For First-Line Lung End?
Zach Hartman•Mon, Apr. 16•14 Comments
AstraZeneca Looks To Prove Itself In The Type 2 Diabetes Market
Terry Chrisomalis•Thu, Mar. 22•10 Comments
I've Sold AstraZeneca Because Of Its Rising Share Price And Weak Results
John Kingham•Fri, Mar. 9•20 Comments
AstraZeneca Scores FDA First, Time To Capitalize Before Competitors Roll In
Terry Chrisomalis•Mon, Feb. 19•7 Comments
Biotech Analysis Central Pharma News: Galectin's Failure, Revance's Positive Results, Novo Nordisk's FDA Win
Terry Chrisomalis•Dec. 6, 2017•28 Comments
Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets 2 FDA Approvals, GW Pharmaceuticals' Price Target Lowered
Avisol Capital Partners•Nov. 15, 2017•3 Comments
Your Daily Pharma Scoop: AstraZeneca's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
Avisol Capital Partners•Oct. 18, 2017•6 Comments
Exploring AstraZeneca's Two-Pronged Assault On Lung Cancer
Zach Hartman•Oct. 18, 2017•9 Comments

News

AstraZeneca aims to build lead in China
SA News•Wed, Sep. 19
AstraZeneca's FASENRA shows safety and sustained efficacy in long-term phase III BORA trial in severe eosinophilic asthma
SA News•Tue, Sep. 18
AstraZeneca's PT010 shows treatment benefit in late-stage COPD study
SA News•Mon, Sep. 17
FDA OKs AstraZeneca's Lumoxiti for type of leukemia
SA News•Thu, Sep. 13•1 Comment
Data analysis shows superiority of Glaxo's Nucala in patients with severe asthma
SA News•Mon, Sep. 10•1 Comment
Tezepelumab granted Breakthrough Therapy designation for the treatment of patients with severe asthma without an eosinophilic phenotype
SA News•Fri, Sep. 7•1 Comment
Biotechs and biopharmas in the red
SA News•Thu, Sep. 6•41 Comments
Adocia's BioChaperone Pramlintide Insulin shows positive action in early-stage study in T1D
SA News•Wed, Sep. 5
Big Pharma in the red after AstraZeneca lupus flop
SA News•Fri, Aug. 31•21 Comments
AstraZeneca's anifrolumab flunks late-stage lupus study; shares down 1% premarket
SA News•Fri, Aug. 31•2 Comments
New formulation of AstraZeneca's long-acting Bydureon OK'd in Europe
SA News•Thu, Aug. 30
Roche to maintain leadership in oncology - Bloomberg Intelligence
SA News•Tue, Aug. 28•15 Comments
23andMe cuts off app developers from raw genetic data
SA News•Fri, Aug. 24•90 Comments
AstraZeneca's Lynparza OK'd in China for ovarian cancer
SA News•Fri, Aug. 24
Oklahoma first state to negotiate efficacy-based drug prices
SA News•Thu, Aug. 23•49 Comments

More From Our Partners

AstraZeneca's Fasenra Long-Term Asthma Study Data Positive
at Zacks.com (Wed, 10:46AM)
AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia
at Zacks.com (Sep 14, 2018)
The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson
at Zacks.com (Sep 10, 2018)
AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status
at Zacks.com (Sep 7, 2018)
The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering
at Benzinga (Sep 7, 2018)